Haemonetics Announces Proposed Convertible Senior Notes Offering BOSTON

Haemonetics Announces Proposed Convertible

Senior Notes Offering

BOSTON, March 1, 2021-Haemonetics

Corporation ("Haemonetics") (NYSE: HAE) today announced its intention to offer, subject to market and other conditions,

$425,000,000 aggregate principal amount of Convertible Senior Notes due 2026 (the "notes") in a private offering (the

"offering") to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the

"Securities Act"). Haemonetics also expects to grant the initial purchasers of the notes an option to purchase up to

an additional $63,750,000 aggregate principal amount of the notes.

The notes will be senior, unsecured obligations

of Haemonetics, will accrue interest payable semi-annually in arrears, and will mature on March 1, 2026, unless earlier repurchased,

redeemed or converted. Noteholders will have the right to convert their notes in certain circumstances and during specified periods.

Haemonetics will settle any conversion amounts of the notes up to the $1,000 principal amount of the notes in cash, and any conversion

amounts in excess of the principal amount in cash, shares of Haemonetics' common stock or a combination thereof, at Haemonetics'

election. The final terms of the notes, including the initial conversion price, interest rate and certain other terms of the notes,

will be determined at the time of pricing.

Haemonetics intends to use a portion of

the net proceeds from the offering to fund the cost of entering into the capped call transactions described below and intends to

use the remainder of the net proceeds to reduce the amount of indebtedness pursuant to Haemonetics' existing credit facility,

working capital and other general corporate purposes. If the initial purchasers exercise their option to purchase additional notes,

then Haemonetics intends to use a portion of the additional net proceeds to fund the cost of entering into additional capped call

transactions as described below.

In connection with the pricing of the notes,

Haemonetics expects to enter into privately negotiated capped call transactions with certain financial institutions (the "option

counterparties"). The capped call transactions are expected to cover, subject to anti-dilution adjustments substantially

similar to those applicable to the notes, the number of shares of Haemonetics' common stock initially underlying the notes.

If the initial purchasers exercise their option to purchase additional notes, Haemonetics expects to enter into additional capped

call transactions with the option counterparties. The capped call transactions are expected generally to reduce or offset the potential

dilution to Haemonetics' common stock upon any conversion of the notes and/or to offset any potential cash payments Haemonetics

is required to make in excess of the principal amount of the converted notes, as the case may be, with such reduction and/or offset

Haemonetics expects that, in connection

with establishing their initial hedges of the capped call transactions, the option counterparties or their respective affiliates

will enter into various derivative transactions with respect to Haemonetics' common stock and/or purchase shares of Haemonetics'

common stock concurrently with or shortly after the pricing of the notes. This activity could increase (or reduce the size of any

decrease in) the market price of Haemonetics' common stock or the notes at that time.

In addition, Haemonetics expects the option

counterparties or their respective affiliates may modify their hedge positions by entering into or unwinding various derivatives

with respect to Haemonetics' common stock and/or purchasing or selling Haemonetics' common stock or other securities

of Haemonetics in secondary market transactions following the pricing of the notes and from time to time prior to the maturity

of the notes (and are likely to do so following any conversion of the notes, any repurchase of the notes by us on any fundamental

change repurchase date, any redemption date or any other date on which the notes are retired by us, in each case if we exercise

our option to terminate the relevant portion of the capped call transactions, where such termination is at our option). This activity

could also cause or avoid an increase or a decrease in the market price of Haemonetics' common stock or the notes, which

could affect a noteholder's ability to convert the notes, and, to the extent the activity occurs during any observation period

related to a conversion of the notes, it could affect the number of shares, if any, and value of the consideration that noteholders

will receive upon conversion of the notes.

The notes will be offered only to persons

reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act. The offer and sale of

the notes and any shares of common stock issuable upon conversion of the notes have not been, and will not be, registered under

the Securities Act or any other securities laws, and unless so registered, the notes and any such shares cannot be offered or sold

except pursuant to an applicable exemption from, or in a transaction not subject to, such registration requirements. This press

release does not constitute an offer to sell, or the solicitation of an offer to buy, the notes or any shares of common stock issuable

upon conversion of the notes, nor will there be any offer or sale of the notes or any such shares, in any state or other jurisdiction

in which such offer, sale or solicitation would be unlawful.

Forward-Looking Statements

This press release includes

forward-looking statements, including, among other things, statements regarding the completion, timing and size of the

proposed offering, the terms of the notes and the capped call transactions and expectations regarding actions of the option

counterparties and their respective affiliates. In addition, other written or oral statements that constitute forward-looking

statements may be made by us or on our behalf. Words such as "expect," "anticipate,"

"intend," "plan," "believe," "could," "should,"

"estimate," "may," "target," "project," or variations of such words and

similar expressions are intended to identify such forward-looking statements. Forward-looking statements represent the

current expectations of Haemonetics regarding future events and are subject to known and unknown risks and uncertainties that

could cause actual results to differ materially from those implied by the forward-looking statements. Among those risks and

uncertainties are (i) the risk that the offering will not be consummated, (ii) changes as a result of market conditions,

including market interest rates, (iii) fluctuations in the trading price and volatility of Haemonetics' common stock,

(iv) the risk that the capped call transactions will not become effective, (v) the impact of general economic, industry or

political conditions in the United States or internationally, including the impact of COVID-19 and any related legislative

and regulatory responses and (vi) risks relating to the Haemonetics business, including those described in Haemonetics'

Annual Report on Form 10-K for the year ended March 28, 2020, filed with the Securities and Exchange Commission. The

forward-looking statements included in this press release speak only as of the date of this press release, and Haemonetics

does not undertake to update the statements included in this press release for subsequent developments, except as may be

Carla Burigatto, Vice President-Communications

Olga Guyette, Director-Investor Relations

All trademarks are the property of their